Dr. Peter Houghton will lead the research collaboration for GCCRI and is widely regarded as a leading expert in pediatric cancer research and in the development of novel approaches to treating childhood cancers
Around 2,000 runners participated in the awareness run organised during World Retinoblastoma Awareness Week
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
Proceeds raised from the duathlon will go towards cancer treatment of children identified by the hospital
Subscribe To Our Newsletter & Stay Updated
